New guidelines emphasize the ongoing colorectal cancer risk in inflammatory bowel disease (IBD) patients despite improved therapies. Developed by UK stakeholders, the guidelines present 73 statements focusing on factors including surveillance intervals, service organization, and the importance of patient collaboration. Key areas include dysplasia management, risk assessment, and the integration of advanced technologies like artificial intelligence. The updated recommendations aim to enhance surveillance quality and patient outcomes while addressing critical training and research priorities.
Journal Article by East JE, Gordon M (…) Morris AJ et 25 al. in Gut
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.